Abstract:To improve hydrolytic stability and biological half-life and anticancer efficacy of the anti-cancer drug melphalan (Mel), a novel esterification strategy was developed to fabricate a pH/enzyme dual-responsive polymer prodrug (mPEG-Mel) via the formation of an ion bond between the carboxyl group in Mel and diazotized p-amino-benzoate-terminated poly(ethylene glycol) monomethyl ether (mPEG-N-2(+)) followed by light-induced conversion of the ionic bond to an ester bond. The prodrug could self-assemble into nanoparticles. Under physiological conditions (pH 7.4), the nanoparticles exhibited a regular core-shell structure with about 100 nm, which could effectively inhibit the hydrolysis of pharmacophores in Mel structure and showed the long-circulation ability. While pH dropped to 5.0, an obvious increase in the nanoparticle size was observed and enhanced by different concentrations of cathepsin B (CTB), reaching a diameter of 675 nm or more in the presence of 2.0 mu g/mL CTB. The nanoparticles showed minimal drug release at pH 7.4 (less than 10% in 24 h); however, drug release could be significantly accelerated in a CTB-containing medium at pH 5.0. Cell experiments showed that the half-inhibitory concentration (IC50) of nanoparticles was 1.00 mu g/mL, which was about 5 times lower than that of free Mel (5.00 mu g/mL), and indicating that the nanoparticles were more cytotoxic to cancer cells (4T1 cells). However, significantly reduced cytostatic effects were observed for normal cells (3T3 cells). In addition, cell uptake observation further supported the above experimental results, a stronger red fluorescence in 4T1 cells was observed for NR-loaded nanoparticles, which meant that the nanoparticles could release drug in response to pH/enzyme stimulation. Thus, mPEG-Mel based pH/enzyme double-response polymer prodrug nanoparticles could effectively enhance drug stability and anticancer efficacy.

Bottlebrush Polymer-Conjugated Melittin Exhibits Enhanced Antitumor Activity and Better Safety Profile

Stable Loading and Delivery of Melittin with Lipid-Coated Polymeric Nanoparticles for Effective Tumor Therapy with Negligible Systemic Toxicity

Metal–Phenolic Network-Facilitated “Foe-to-Friend” Conversion of Melittin for Cancer Immunotherapy with Boosted Abscopal Effect

Acid-Activated Melittin for Targeted and Safe Antitumor Therapy.

Genetically engineered nano-melittin vesicles for multimodal synergetic cancer therapy

Hybrid Melittin Cytolytic Peptide-Driven Ultrasmall Lipid Nanoparticles Block Melanoma Growth <i>in Vivo</i>

Hybrid melittin cytolytic Peptide-driven ultrasmall lipid nanoparticles block melanoma growth in vivo.

Homologous polydopamine ameliorates haemolysis of melittin for enhancing its anticancer efficacy

Application of bee venom and its main constituent melittin for cancer treatment

Melphalan-monomethoxypolyethylene Glycol-Based Ph/enzyme Double-Response Polymer Prodrug Nanoparticles for Enhanced Drug Stability and Anticancer Efficacy

Anti-cancer Effect of Melittin-Au25(mha)18 Complexes on Human Cervical Cancer HeLa Cells

Turning Toxicants into Safe Therapeutic Drugs: Cytolytic Peptide−Photosensitizer Assemblies for Optimized In Vivo Delivery of Melittin

Synthesis, Characterization of Liposomes Modified with Biosurfactant MEL-A Loading Betulinic Acid and Its Anticancer Effect in HepG2 Cell

Melittin-encapsulating Peptide Hydrogels for Enhanced Delivery of Impermeable Anticancer Peptides.

Design, synthesis, and antiproliferative activities of stapled melittin peptides

Melittin-incorporated nanomedicines for enhanced cancer immunotherapy

Melittin-Based Nano-Delivery Systems for Cancer Therapy

Melittin and phospholipase A2: Promising anti-cancer candidates from bee venom

Graphene Oxide-Based Magnetic Nanocomposites for the Delivery of Melittin to Cervical Cancer HeLa Cells.

One-step and facile synthesis of peptide-like poly(melphalan) nanodrug for cancer therapy

Nanostructured Peptidotoxins As Natural Pro-Oxidants Induced Cancer Cell Death Via Amplification of Oxidative Stress.